Gregory Francis Guzauskas

Gregory Francis Guzauskas

Auto-generated profile, based on publicly available information

Gregory Francis Guzauskas

A Department of Pharmacy , University of Washington , Seattle , WA , USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in Annals of Internal Medicine
Verified
Journal Article
Closed access
GGGregory F. Guzauskas
Gregory F. Guzauskas
SGShawn Garbett
Shawn Garbett
ZZZilu Zhou
Zilu Zhou
JSJonathan S. Schildcrout
Jonathan S. Schildcrout
JGJohn A. Graves
John A. Graves
JPJosh F. Peterson
Josh F. Peterson
The cost-effectiveness of screening the U.S. population for Centers for Disease Control and Prevention (CDC) Tier 1 genomic conditions is unknown. To estimate the cost-effectiveness of simultaneous genomic screening for Lynch syndrome (LS), hereditary breast and ovarian cancer syndrome (HBOC), and familial hypercholesterolemia (FH). Decision analytic Markov model. Published literature. Separate age-based cohorts (ages 20 to 60 years at time of screening) of racially and ethnically representative U.S. adults. Lifetime. U.S. health care payer. Population genomic screening using clinical sequencing with a restricted panel of high-evidence genes, cascade testing of first-degree relatives, and recommended preventive interventions for identified probands. Incident breast, ovarian, and colorectal cancer cases; incident cardiovascular events; quality-adjusted survival; and costs. Screening 100 000 unselected 30-year-olds resulted in 101 (95% uncertainty interval [UI], 77 to 127) fewer overall cancer cases and 15 (95% UI, 4 to 28) fewer cardiovascular events and an increase of 495 quality-adjusted life-years (QALYs) (95% UI, 401 to 757) at an incremental cost of $33.9 million (95% UI, $27.0 million to $41.1 million). The incremental cost-effectiveness ratio was $68 600 per QALY gained (95% UI, $41 800 to $88 900). Screening 30-, 40-, and 50-year-old cohorts was cost-effective in 99%, 88%, and 19% of probabilistic simulations, respectively, at a $100 000-per-QALY threshold. The test costs at which screening 30-, 40-, and 50-year-olds reached the $100 000-per-QALY threshold were $413, $290, and $166, respectively. Variant prevalence and adherence to preventive interventions were also highly influential parameters. Population averages for model inputs, which were derived predominantly from European populations, vary across ancestries and health care environments. Population genomic screening with a restricted panel of high-evidence genes associated with 3 CDC Tier 1 conditions is likely to be cost-effective in U.S. adults younger than 40 years if the testing cost is relatively low and probands have access to preventive interventions. National Human Genome Research Institute.

20 May 2019 in Journal of Medical Economics
Verified
Journal Article
Open access
GGGregory F Guzauskas
Gregory F Guzauskas
EPErqi L Pollom
Erqi L Pollom
VSVolker W Stieber
Volker W Stieber
BWBruce C M Wang
Bruce C M Wang
LGLouis P Garrison
Louis P Garrison
Purpose: The EF-14 trial demonstrated that adding tumor treating fields (TTFields) to maintenance temozolomide (TMZ) significantly extends progression-free survival (PFS) and overall survival (OS) for newly diagnosed glioblastoma (GBM) patients. We assessed the cost-effectiveness of TTFields and TMZ for newly diagnosed GBM from the U.S. healthcare system perspective. Methods and Materials: Outcomes for newly diagnosed GBM patients were estimated over a lifetime horizon using an area under the curve model with three states: stable disease, progressive disease, or death. The survival model integrated the 5-year EF-14 trial results with long-term GBM epidemiology data and U.S. background mortality rates. Adverse event rates were derived from the EF-14 trial data. Utility values to determine quality-adjusted life-years, adverse event costs and supportive care costs were obtained from published literature. We applied a 3% discount rate to future costs and outcomes. One-way and probabilistic sensitivity analyses were performed to assess result uncertainty due to parameter variability. Results: Treatment with TTFields and TMZ was estimated to result in a mean increase in survival of 1.25 life years (95% credible range [CR]: 0.89 to 1.67) and 0.96 quality-adjusted life years (QALYs) (95% CR: 0.67 to 1.30) compared to treatment with TMZ alone. The incremental total cost was $188,637 (95% CR: $145,324 to $225,330). The incremental cost-effectiveness ratio (ICER) was $150,452 per life year gained and $197,336 per QALY gained. The model was most sensitive to changes in the cost of TTFields treatment. Conclusions: Adding TTFields to maintenance TMZ resulted in a substantial increase in the estimated mean lifetime survival and quality-adjusted survival for newly diagnosed GBM patients. Treatment with TTFields can be considered cost-effective within the reported range of willingness-to-pay thresholds in the United States.

Verified
Journal Article
Open access
PDF file
YCYixi Chen
Yixi Chen
GGGregory F. Guzauskas
Gregory F. Guzauskas
CGChengming Gu
Chengming Gu
BWBruce C. M. Wang
Bruce C. M. Wang
WFWesley Furnback
Wesley Furnback
LGLouis Garrison
Louis Garrison
The “big data” era represents an exciting opportunity to utilize powerful new sources of information to reduce clinical and health economic uncertainty on an individual patient level. In turn, health economic outcomes research (HEOR) practices will need to evolve to accommodate individual patient–level HEOR analyses. We propose the concept of “precision HEOR”, which utilizes a combination of costs and outcomes derived from big data to inform healthcare decision-making that is tailored to highly specific patient clusters or individuals. To explore this concept, we discuss the current and future roles of HEOR in health sector decision-making, big data and predictive analytics, and several key HEOR contexts in which big data and predictive analytics might transform traditional HEOR into precision HEOR. The guidance document addresses issues related to the transition from traditional to precision HEOR practices, the evaluation of patient similarity analysis and its appropriateness for precision HEOR analysis, and future challenges to precision HEOR adoption. Precision HEOR should make precision medicine more realizable by aiding and adapting healthcare resource allocation. The combined hopes for precision medicine and precision HEOR are that individual patients receive the best possible medical care while overall healthcare costs remain manageable or become more cost-efficient.

25 February 2022 in Genetics in Medicine
Verified
Journal Article
Closed access
GGGregory F. Guzauskas
Gregory F. Guzauskas
SJShangqing Jiang
Shangqing Jiang
SGShawn Garbett
Shawn Garbett
ZZZilu Zhou
Zilu Zhou
SSScott J. Spencer
Scott J. Spencer
DVDavid L. Veenstra
David L. Veenstra

30 July 2022 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
SSScott J. Spencer
Scott J. Spencer
LJLaney Jones
Laney Jones
GGGregory F. Guzauskas
Gregory F. Guzauskas
JHJing Hao
Jing Hao
MWMarc Williams
Marc Williams
DVDavid L. Veenstra
David L. Veenstra

1 January 2021 in Journal of Medical Economics
Verified
Journal Article
Open access
NLNanxin Li
Nanxin Li
ESEileen K. Sawyer
Eileen K. Sawyer
KMKonrad Maruszczyk
Konrad Maruszczyk
GGGreg Guzauskas
Greg Guzauskas
MSMarta T. Slomka
Marta T. Slomka
MRMichael Recht
Michael Recht
Hemophilia B (HB) is a rare congenital disorder characterized by bleeding-related complications which are managed by prophylactic or post-bleeding event (“on-demand”) replacement of clotting factor...